Skip to main content
OpenTrials
Completed

NCT Number: NCT02185898

Evaluation of Environmental Emissions From Electronic Cigarettes and Tobacco-Burning Cigarettes

This study will assess environmental emissions of selected compounds in a test chamber after cigarette smoking or e-cigarette vaping.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

21 year–99 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Clinical Research Atlanta

Stockbridge, Georgia, 30281, United States

About this study

Secondhand smoke is the aged and diluted combination of smoke exhaled by a smoker and sidestream smoke (smoke from the lit end of a cigarette). Electronic cigarettes are different from tobacco-burning cigarettes in that they produce vapor, not smoke. For consistency with common usage, secondhand smoke (SHS) refers to true secondhand smoke from cigarettes and secondhand vapor from e-cigarettes.

The goals of this study are to 1) increase understanding of the composition of SHS from e-cigarettes, 2) quantitatively compare the amount of SHS generated by e-cigarettes and a market sample of commercial e-cigarettes to leading brand styles of commercial tobacco-burning cigarettes, and 3) quantitate the emission factors of e-cigarettes including the market-sample e-cigarettes.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Able to read, understand, and willing to sign an Informed Consent Form (ICF) and complete questionnaires written in English.
  • Generally healthy males or females, 21 years of age or older at Screening.
  • Able to meet cohort-specific requirements as follows:

Cohort 1 - Leading U.S. tobacco-burning non-menthol cigarette, and

Cohort 2 - Leading U.S. tobacco-burning menthol cigarette:

  • self-reports at the Screening Visit smoking at least 5 cigarettes per day and inhaling the smoke, for at least 3 months prior to Screening
  • self-reports smoking Leading U.S. tobacco-burning non-menthol cigarette or Leading U.S. tobacco-burning menthol cigarette as usual brand (UB) cigarettes [UB cigarette is defined as the cigarette brand style currently smoked most frequently by the participant];

Cohort 3 - Electronic cigarette #1 smokers, and

Cohort 4 - Electronic cigarette #2 smokers:

  • self-reports at the Screening Visit smoking a non-menthol e-cigarette at least once per day, for at least 3 months prior to Screening;
  • willing to switch from using their current e-cigarette brand style to using a different e-cigarette brand style during the study;

Cohort 5 - Electronic cigarette #3 smokers:

  • self-reports at the Screening Visit smoking a menthol e-cigarette at least once per day, for at least 3 months prior to Screening;
  • willing to switch from using their current e-cigarette brand style to using a different e-cigarette brand style during the study;

Cohort 6 - U.S Market-sample electronic cigarette smokers:

  • self-reports at the Screening Visit smoking the selected U.S. market-sample e-cigarettes (menthol or non-menthol) at least once per day, for at least three months prior to Screening;
  • willing to continue exclusive use of their preferred style (flavor) of e-cigarette during the study.
  • Females of childbearing potential must be willing to use a form of contraception acceptable to the Investigator from the time of signing informed consent until study discharge or be surgically sterile for at least 90 days prior to enrollment;
  • Able to safely perform the required study procedures, as determined by the Investigator.

Exclusion criteria

  • Clinically significant or unstable/uncontrolled acute or chronic medical conditions at Screening, as determined by the Investigator, that would preclude a participant from participating safely in the study (e.g., hypertension, asthma, or other lung disease; cardiac disease; neurological disease; or psychiatric disorders) based on screening assessments such as safety labs and medical history or physical examination at Enrollment;
  • Self-reports or safety labs indicate diabetes;
  • At risk for heart disease, as determined by the Investigator;
  • Use of medicine for treatment of depression or asthma;
  • Systolic blood pressure of ≥150 mmHg or a diastolic blood pressure of ≥95 mmHg, measured after being seated for 5 minutes;
  • Postponing a decision to quit smoking (defined as planning a quit attempt within 30 days of the Screening Visit) to participate in this study;
  • Employed by a tobacco company, the study site, or environmental test chamber vendor;
  • Females who have a positive pregnancy test, are pregnant, breastfeeding, or intend to become pregnant during the course of the study;
  • History of claustrophobia;
  • Regularly exposed to solvent fumes or gasoline (e.g., painter, gas-station mini mart employee);
  • Determined by the Investigator to be inappropriate for this study, including a participant who is unable to communicate or unwilling to cooperate with the clinical staff.

Treatment and study plan

Leading U.S. non-menthol cigarette

Other

Tobacco-burning non-menthol cigarette

Other names: Marlboro Gold Pack Box

Leading U.S. menthol cigarette

Other

Tobacco-burning menthol cigarette

Other names: Newport Box

Electronic Cigarette #1

Other

Electronic cigarette

Other names: VUSE® Digital Vapor Cigarette (menthol flavor, 29 mg nicotine)

Electronic Cigarette #2

Other

Electronic cigarette

Other names: VUSE® Digital Vapor Cigarette (original flavor, 29 mg nicotine)

Electronic Cigarette #3

Other

Electronic cigarette

Other names: VUSE® Digital Vapor Cigarette (original flavor, 14 mg nicotine)

U.S. Market-sample electronic cigarettes

Other

Marketed electronic cigarettes

Other names: blu™ (any variety) and NJOY® (any variety)

Primary outcomes

  1. To assess differences in levels of selected SHS constituents in an environmental test chamber after human smoking of e-cigarette #1, #2, and #3 compared to after human smoking of tobacco-burning cigarettes.

    Time frame: 2 weeks for participants in Cohorts 1 and 2; and approximately 4 weeks for participants in Cohorts 3, 4, and 5

Secondary outcomes

  1. To determine selected SHS constituent emission factors for each tobacco-burning cigarette, each e-cigarette, and the market-sample e-cigarettes (collectively).

    Time frame: 2 weeks for participants in Cohorts 1, 2, and 6; and approximately 4 weeks for participants in Cohorts 3, 4, and 5

  2. To assess the differences in levels of selected SHS constituents in an environmental test chamber after human smoking of e-cigarettes and tobacco-burning cigarettes compared to after a non-smoking blank condition.

    Time frame: 2 weeks for participants in Cohorts 1, 2, and 6; and approximately 4 weeks for participants in Cohorts 3, 4, and 5

  3. To assess differences in levels of additional selected SHS constituents in an environmental test chamber after human smoking of e-cigarettes compared to after human smoking of tobacco-burning cigarettes.

    Time frame: 2 weeks for participants in Cohorts 1, 2, and 6; and approximately 4 weeks for participants in Cohorts 3, 4, and 5

Sponsors and collaborators

Lead sponsor

R.J. Reynolds Vapor Company

Industry

Collaborators

  • Covance
  • MAS (Materials Analytical Services), LLC
  • R.J. Reynolds Tobacco Company

Registry information

Official study title

A Single-Center Evaluation of Environmental Emissions From Electronic Cigarettes and Tobacco-Burning Cigarettes

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Jul 10, 2014
Registry last updated
Jun 1, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.